Teva Invests $10M In Heptares’ Migraine Treatment

November 26, 2015 | Israeli pharmaceutical giant Teva and UK-based Heptares Therapeutics, a unit of Sosei Group Corporation, have announced a licensing and drug-discovery agreement under which Teva will receive exclusive global rights to develop, manufacture and commercialize novel, small-molecule calcitonin gene-related peptide (CGRP) antagonists discovered by Heptares for the treatment of migraine headaches. Heptares will receive an upfront payment of $10 million, and will be eligible to receive additional research, development and commercialization milestone payments of up to $400 million. In addition, Heptares will be eligible to receive royalties on net sales of products resulting from the partnership.